Cytokinetics Inc.'s shares (NASDAQ:CYTK) were down 65 cents, or 22.2 percent, to close at $2.28 Monday despite "encouraging" results in amyotrophic lateral sclerosis (ALS) patients from a Phase IIa evidence-of-effect trial of CK-2017357, a fast skeletal muscle troponin activator and the lead drug candidate in the company's skeletal muscle contractility program.